18:00 Mon 30 Mar 2020
Frontier IP Group - Elute Intelligence’s AI to back COVID-19 research
RNS REACH
AIM: FIPP
("
Portfolio news - Elute Intelligence uses novel artificial intelligence technology to support scientists researching COVID-19
The Document Reader is aimed at supporting scientists researching the disease and related coronaviruses by making it easier and quicker for them to find relevant research.
Elute Intelligence launches dedicated COVID-19 Document Reader to help scientists find vital research more rapidly
The COVID-19 Document Reader draws on Elute's novel advanced software tools to intelligently search large and complex databases to identify relevant information swiftly and effectively. It is available at https://elute.info.
The databases being used include a subset of PubMed, an online resource of more than 30 million citations for papers drawn from Medline, life science journals, books and other sources. Researchers will be able to search this for articles mentioning terms related to the current COVID-19 outbreak, such as coronavirus, COVID, MERS, or SARS. Elute is proactively working with researchers to identify additional datasets.
Elute's artificial intelligence searches, compares and analyses documents to identify similarities between them by mimicking the way people read. Researchers enter an entire paper already identified as of interest to find other relevant research. They can also create their own documents defining their own interests to enter into the Document Reader to refine searches still further.
This means the approach is very different to conventional keyword or Boolean search technologies. A patent application has been filed to protect developments of the technology.
Elute is already talking to a number of partners to support and publicise the COVID-19 Document Reader.
Elute was incorporated last year from an existing
ENQUIRIES
|
T: 020 7332 2338 |
|
|
|
M: 07464 546 025 |
Group website: www.frontierip.co.uk |
|
|
T: 0203 328 5656 |
|
|
ABout
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE